Sanofi Genzyme pauses haemophilia clinical development program for fitusiran

Program for this once-once monthly, subcutaneously dosed non-factor-replacement therapy that leverages small interfering RNA to target and decrease antithrombin has been paused to allow investigation of reports of non-fatal thrombotic events in patients in the trials.

Biospace Inc.